NEW YORK, April 29 (Reuters) - Gilead Sciences GILD.O has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying kickbacks to doctors who agreed to prescribe its HIV drugs, the U.S. attorney's office in Manhattan said on Tuesday.
The settlement resolves claims that Gilead paid honoraria, meals and travel expenses to doctors who attended Gilead speaker events to induce them to prescribe several HIV drugs.
U.S. Attorney Jay Clayton said this violated the federal False Claims Act by causing claims to be paid by federal healthcare programs.
(Reporting by Jonathan Stempel in New York; Editing by Chris Reese)
((jon.stempel@thomsonreuters.com; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.